|
1
|
Lin L, Li Z, Yan L, Liu Y, Yang H and Li
H: Global, regional, and national cancer incidence and death for 29
cancer groups in 2019 and trends analysis of the global cancer
burden, 1990–2019. J Hematol Oncol. 14:1972021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
global cancer statistics? Cancer Commun (Lond). 39:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pan C, Liu H, Robins E, Song W, Liu D, Li
Z and Zheng L: Next-generation immuno-oncology agents: Current
momentum shifts in cancer immunotherapy. J Hematol Oncol.
13:292020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Jiang L, Wen T, Guo X, Shao X, Qu
H, Chen X, Song Y, Wang F, Qu X and Li Z: Trends in the research
into immune checkpoint blockade by anti-PD1/PDL1 antibodies in
cancer immunotherapy: A bibliometric study. Front Pharmacol.
12:6709002021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai
C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, et al:
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer
and more effective cancer immunotherapy. Cell Res. 9:609–627. 2019.
View Article : Google Scholar
|
|
6
|
Smith KM and Desai J: Nivolumab for the
treatment of colorectal cancer. Expert Rev Anticancer Ther.
18:611–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gonzalez H, Hagerling C and Werb Z: Roles
of the immune system in cancer: From tumor initiation to metastatic
progression. Genes Dev. 32:1267–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ribatti D: The concept of immune
surveillance against tumors. The first theories. Oncotarget.
8:7175–7180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Finn OJ: Human tumor antigens yesterday,
today, and tomorrow. Cancer Immunol Res. 5:347–354. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Verginelli F, Pisacane A, Gambardella G,
D'Ambrosio A, Candiello E, Ferrio M, Panero M, Casorzo L, Benvenuti
S, Cascardi E, et al: Cancer of unknown primary stem-like cells
model multi-organ metastasis and unveil liability to MEK
inhibition. Nat Commun. 12:24982021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng H, Yang W, Zhou Z, Tian R, Lin L, Ma
Y, Song J and Chen X: Targeted scavenging of extracellular ROS
relieves suppressive immunogenic cell death. Nat Commun.
11:49512020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren Y, Kumar A, Das JK, Peng HY, Wang L,
Balllard D, Xiong X, Ren X, Zhang Y, Yang JM and Song J: Tumorous
expression of NAC1 restrains antitumor immunity through the
LDHA-mediated immune evasion. J Immunother Cancer. 10:e0048562022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bazett M, Costa AM, Bosiljcic M, Anderson
RM, Alexander MP, Wong SWY, Dhanji S, Chen JM, Pankovich J, Lam S,
et al: Harnessing innate lung anti-cancer effector functions with a
novel bacterial-derived immunotherapy. Oncoimmunology.
7:e13988752017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosewell Shaw A, Porter C, Biegert G,
Jatta L and Suzuki M: HydrAd: A helper-dependent adenovirus
targeting multiple immune pathways for cancer immunotherapy.
Cancers (Basel). 14:27692022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Li Z, Skrzypczynska KM, Fang Q,
Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A, et al:
Single-cell analyses inform mechanisms of myeloid-targeted
therapies in colon cancer. Cell. 181:442–459.e29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krausgruber T, Fortelny N, Fife-Gernedl V,
Senekowitsch M, Schuster LC, Lercher A, Nemc A, Schmidl C, Rendeiro
AF, Bergthaler A and Bock C: Structural cells are key regulators of
organ-specific immune responses. Nature. 583:296–302. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahmad HI, Jabbar A, Mushtaq N, Javed Z,
Hayyat MU, Bashir J, Naseeb I, Abideen ZU, Ahmad N and Chen J:
Immune tolerance vs immune resistance: The interaction between host
and pathogens in infectious diseases. Front Vet Sci. 9:8274072022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bettcher BM, Tansey MG, Dorothée G and
Heneka MT: Peripheral and central immune system crosstalk in
Alzheimer disease-a research prospectus. Nat Rev Neurol.
17:689–701. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morsink MAJ, Willemen NGA, Leijten J,
Bansal R and Shin SR: Immune organs and immune cells on a chip: An
overview of biomedical applications. Micromachines (Basel).
11:8492020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benci JL, Johnson LR, Choa R, Xu Y, Qiu J,
Zhou Z, Xu B, Ye D, Nathanson KL, June CH, et al: Opposing
functions of interferon coordinate adaptive and innate immune
responses to cancer immune checkpoint blockade. Cell.
178:933–948.e14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gangopadhyay K, Roy S, Sen Gupta S,
Chandradasan AC, Chowdhury S and Das R: Regulating the
discriminatory response to antigen by T-cell receptor. Biosci Rep.
42:BSR202120122022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Druszczyńska M, Godkowicz M, Kulesza J,
Wawrocki S and Fol M: Cytokine receptors-regulators of
antimycobacterial immune response. Int J Mol Sci. 23:11122022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Šket T, Ramuta TŽ, Starčič Erjavec M and
Kreft ME: The role of innate immune system in the human amniotic
membrane and human amniotic fluid in protection against
intra-amniotic infections and inflammation. Front Immunol.
12:7353242021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He L, Valignat MP, Zhang L, Gelard L,
Zhang F, Le Guen V, Audebert S, Camoin L, Fossum E, Bogen B, et al:
ARHGAP45 controls naïve T- and B-cell entry into lymph nodes and
T-cell progenitor thymus seeding. EMBO Rep. 22:e521962021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yiwen Z, Shilin G, Yingshi C, Lishi S,
Baohong L, Chao L, Linghua L, Ting P and Hui Z: Efficient
generation of antigen-specific CTLs by the BAFF-activated human B
Lymphocytes as APCs: A novel approach for immunotherapy.
Oncotarget. 7:77732–77748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nicholson LB: The immune system. Essays
Biochem. 60:275–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vila-Leahey A, MacKay A,
Portales-Cervantes L, Weir GM, Merkx-Jacques A and Stanford MM:
Generation of highly activated, antigen-specific tumor-infiltrating
CD8+ T cells induced by a novel T cell-targeted
immunotherapy. Oncoimmunology. 9:17825742020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schönefeldt S, Wais T, Herling M, Mustjoki
S, Bekiaris V, Moriggl R and Neubauer HA: The diverse roles of γδ T
cells in cancer: From rapid immunity to aggressive lymphoma.
Cancers (Basel). 13:62122021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leko V and Rosenberg SA: Identifying and
targeting human tumor antigens for T cell-based immunotherapy of
solid tumors. Cancer Cell. 38:454–472. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J, Fu M, Wang M, Wan D, Wei Y and Wei
X: Cancer vaccines as promising immuno-therapeutics: Platforms and
current progress. J Hematol Oncol. 15:282022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu YT and Sun ZJ: Turning cold tumors
into hot tumors by improving T-cell infiltration. Theranostics.
11:5365–5386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanimine N, Ohira M, Tahara H, Ide K,
Tanaka Y, Onoe T and Ohdan H: Strategies for deliberate induction
of immune tolerance in liver transplantation: From preclinical
models to clinical application. Front Immunol. 11:16152020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hargadon KM: Tumor microenvironmental
influences on dendritic cell and T cell function: A focus on
clinically relevant immunologic and metabolic checkpoints. Clin
Transl Med. 10:374–411. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elizondo DM, Andargie TE, Kubhar DS,
Gugssa A and Lipscomb MW: CD40-CD40L cross-talk drives fascin
expression in dendritic cells for efficient antigen presentation to
CD4+ T cells. Int Immunol. 29:121–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morris DL, Oatmen KE, Mergian TA, Cho KW,
DelProposto JL, Singer K, Evans-Molina C, O'Rourke RW and Lumeng
CN: CD40 promotes MHC class II expression on adipose tissue
macrophages and regulates adipose tissue CD4+ T cells
with obesity. J Leukoc Biol. 99:1107–1119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Y, Slone N, Chrisikos TT, Kyrysyuk O,
Babcock RL, Medik YB, Li HS, Kleinerman ES and Watowich SS: Vaccine
efficacy against primary and metastatic cancer with in
vitro-generated CD103+ conventional dendritic cells. J
Immunother Cancer. 8:e0004742020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Krishnaswamy JK, Gowthaman U, Zhang B,
Mattsson J, Szeponik L, Liu D, Wu R, White T, Calabro S, Xu L, et
al: Migratory CD11b+ conventional dendritic cells induce
T follicular helper cell-dependent antibody responses. Sci Immunol.
2:eaam91692017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roselli E, Araya P, Núñez NG, Gatti G,
Graziano F, Sedlik C, Benaroch P, Piaggio E and Maccioni M: TLR3
activation of intratumoral CD103+ dendritic cells
modifies the tumor infiltrate conferring anti-tumor immunity. Front
Immunol. 10:5032019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Koh YC, Yang G, Lai CS, Weerawatanakorn M
and Pan MH: Chemopreventive effects of phytochemicals and medicines
on M1/M2 polarized macrophage role in inflammation-related
diseases. Int J Mol Sci. 19:22082018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Castro F, Cardoso AP, Gonçalves RM, Serre
K and Oliveira MJ: Interferon-gamma at the crossroads of tumor
immune surveillance or evasion. Front Immunol. 9:8472018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song X, Traub B, Shi J and Kornmann M:
Possible roles of interleukin-4 and −13 and their receptors in
gastric and colon cancer. Int J Mol Sci. 22:7272021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Babazadeh S, Nassiri SM, Siavashi V,
Sahlabadi M, Hajinasrollah M and Zamani-Ahmadmahmudi M: Macrophage
polarization by MSC-derived CXCL12 determines tumor growth. Cell
Mol Biol Lett. 26:302021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oshi M, Tokumaru Y, Asaoka M, Yan L,
Satyananda V, Matsuyama R, Matsuhashi N, Futamura M, Ishikawa T,
Yoshida K, et al: M1 Macrophage and M1/M2 ratio defined by
transcriptomic signatures resemble only part of their conventional
clinical characteristics in breast cancer. Sci Rep. 10:165542020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He M, Wang Y, Zhang G, Cao K, Yang M and
Liu H: The prognostic significance of tumor-infiltrating
lymphocytes in cervical cancer. J Gynecol Oncol. 32:e322021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu A, Zhang L, Yuan J, Babikr F, Freywald
A, Chibbar R, Moser M, Zhang W, Zhang B, Fu Z and Xiang J: TLR9
agonist enhances radiofrequency ablation-induced CTL responses,
leading to the potent inhibition of primary tumor growth and lung
metastasis. Cell Mol Immunol. 16:820–832. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Crawshaw A, Kendrick YR, McMichael AJ and
Ho LP: Abnormalities in iNKT cells are associated with impaired
ability of monocytes to produce IL-10 and suppress T-cell
proliferation in sarcoidosis. Eur J Immunol. 44:2165–2174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang YL, Gong Y, Lv Z, Li L and Yuan Y:
Expression of PD1/PDL1 in gastric cancer at different
microsatellite status and its correlation with infiltrating immune
cells in the tumor microenvironment. J Cancer. 12:1698–1707. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Weigelin B, Bolaños E, Teijeira A,
Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A,
Quetglas JI, Wagena E, Sánchez-Paulete AR, et al: Focusing and
sustaining the antitumor CTL effector killer response by agonist
anti-CD137 mAb. Proc Natl Acad Sci USA. 112:7551–7556. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Baik AH, Tsai KK, Oh DY and Aras MA:
Mechanisms and clinical manifestations of cardiovascular toxicities
associated with immune checkpoint inhibitors. Clin Sci (Lond).
135:703–724. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Turula H, Bragazzi Cunha J, Mainou BA,
Ramakrishnan SK, Wilke CA, Gonzalez-Hernandez MB, Pry A, Fava J,
Bassis CM, Edelman J, et al: Natural secretory immunoglobulins
promote enteric viral infections. J Virol. 92:e00826–18. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ehrlich P: Address in pathology, on
chemiotherapy: Delivered before the seventeenth international
congress of medicine. Br Med J. 2:353–359. 1913. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
He Q, Liu Z, Liu Z, Lai Y, Zhou X and Weng
J: TCR-like antibodies in cancer immunotherapy. J Hematol Oncol.
12:992019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Byeon HK, Ku M and Yang J: Beyond EGFR
inhibition: Multilateral combat strategies to stop the progression
of head and neck cancer. Exp Mol Med. 51:1–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Santoro V, Jia R, Thompson H, Nijhuis A,
Jeffery R, Kiakos K, Silver AR, Hartley JA and Hochhauser D: Role
of reactive oxygen species in the abrogation of oxaliplatin
activity by cetuximab in colorectal cancer. J Natl Cancer Inst.
108:djv3942015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen KF, Chen HL, Shiau CW, Liu CY, Chu
PY, Tai WT, Ichikawa K, Chen PJ and Cheng AL: Sorafenib and its
derivative SC-49 sensitize hepatocellular carcinoma cells to
CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br J Pharmacol.
168:658–672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fenwarth L, Fournier E, Cheok M, Boyer T,
Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H,
Preudhomme C and Duployez N: Biomarkers of gemtuzumab ozogamicin
response for acute myeloid leukemia treatment. Int J Mol Sci.
21:56262020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Boyer-Suavet S, Andreani M, Lateb M,
Savenkoff B, Brglez V, Benzaken S, Bernard G, Nachman PH, Esnault V
and Seitz-Polski B: Neutralizing anti-rituximab antibodies and
relapse in membranous nephropathy treated with rituximab. Front
Immunol. 10:30692020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Strohl WR and Naso M: Bispecific T-Cell
redirection versus chimeric antigen receptor (CAR)-T cells as
approaches to kill cancer cells. Antibodies (Basel). 8:412019.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Huo Y, Sheng Z, Lu DR, Ellwanger DC, Li
CM, Homann O, Wang S, Yin H and Ren R: Blinatumomab-induced T cell
activation at single cell transcriptome resolution. BMC Genomics.
22:1452021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Davis SK, Selva KJ, Kent SJ and Chung AW:
Serum IgA Fc effector functions in infectious disease and cancer.
Immunol Cell Biol. 98:276–286. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Brandsma AM, Bondza S, Evers M, Koutstaal
R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW and Ten
Broeke T: Potent Fc receptor signaling by IgA leads to superior
killing of cancer cells by neutrophils compared to IgG. Front
Immunol. 10:7042019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Leoh LS, Daniels-Wells TR and Penichet ML:
IgE immunotherapy against cancer. Curr Top Microbiol Immunol.
388:109–149. 2015.PubMed/NCBI
|
|
65
|
Chauhan J, McCraw AJ, Nakamura M, Osborn
G, Sow HS, Cox VF, Stavraka C, Josephs DH, Spicer JF, Karagiannis
SN and Bax HJ: IgE antibodies against cancer: Efficacy and safety.
Antibodies (Basel). 9:552020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
El-Kadiry AE, Rafei M and Shammaa R: Cell
therapy: Types, regulation, and clinical benefits. Front Med
(Lausanne). 8:7560292021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mora Román JJ, Del Campo M, Villar J,
Paolini F, Curzio G, Venuti A, Jara L, Ferreira J, Murgas P,
Lladser A, et al: Immunotherapeutic potential of mollusk
hemocyanins in combination with human vaccine adjuvants in murine
models of oral cancer. J Immunol Res. 2019:70769422019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kurosawa S, Mizuno S, Arai Y, Masuko M,
Kanda J, Kohno K, Onai D, Fukuda T, Ozawa Y, Katayama Y, et al:
Syngeneic hematopoietic stem cell transplantation for acute myeloid
leukemia: A propensity score-matched analysis. Blood Cancer J.
11:1592021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lin J, Wang H, Liu C, Cheng A, Deng Q, Zhu
H and Chen J: Dendritic cells: Versatile players in renal
transplantation. Front Immunol. 12:6545402021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Markov O, Oshchepkova A and Mironova N:
Immunotherapy based on dendritic cell-targeted/-derived
extracellular vesicles-A novel strategy for enhancement of the
anti-tumor immune response. Front Pharmacol. 10:11522019.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Blando J, Sharma A, Higa MG, Zhao H, Vence
L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, et al:
Comparison of immune infiltrates in melanoma and pancreatic cancer
highlights VISTA as a potential target in pancreatic cancer. Proc
Natl Acad Sci USA. 116:1692–1697. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cui X and Snapper CM: Epstein barr virus:
Development of vaccines and immune cell therapy for EBV-associated
diseases. Front Immunol. 12:7344712021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Luo XH, Meng Q, Rao M, Liu Z, Paraschoudi
G, Dodoo E and Maeurer M: The impact of inflationary
cytomegalovirus-specific memory T cells on anti-tumour immune
responses in patients with cancer. Immunology. 155:294–308. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pesch T, Bonati L, Kelton W, Parola C,
Ehling RA, Csepregi L, Kitamura D and Reddy ST: Molecular design,
optimization, and genomic integration of chimeric B cell receptors
in murine B cells. Front Immunol. 10:26302019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Stoiber S, Cadilha BL, Benmebarek MR,
Lesch S, Endres S and Kobold S: Limitations in the design of
chimeric antigen receptors for cancer therapy. Cells. 8:4722019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kasala D, Yoon AR, Hong J, Kim SW and Yun
CO: Evolving lessons on nanomaterial-coated viral vectors for local
and systemic gene therapy. Nanomedicine (Lond). 11:1689–1713. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Muliaditan T, Halim L, Whilding LM, Draper
B, Achkova DY, Kausar F, Glover M, Bechman N, Arulappu A, Sanchez
J, et al: Synergistic T cell signaling by 41BB and CD28 is
optimally achieved by membrane proximal positioning within parallel
chimeric antigen receptors. Cell Rep Med. 2:1004572021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Verheye E, Bravo Melgar J, Deschoemaeker
S, Raes G, Maes A, De Bruyne E, Menu E, Vanderkerken K, Laoui D and
De Veirman K: Dendritic cell-based immunotherapy in multiple
myeloma: Challenges, opportunities, and future directions. Int J
Mol Sci. 23:9042022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Steinman RM and Cohn ZA: Identification of
a novel cell type in peripheral lymphoid organs of mice. I.
Morphology, quantitation, tissue distribution. J Exp Med.
137:1142–1162. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Steinman RM and Banchereau J: Taking
dendritic cells into medicine. Nature. 449:419–426. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Handy CE and Antonarakis ES: Sipuleucel-T
for the treatment of prostate cancer: Novel insights and future
directions. Future Oncol. 14:907–917. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Artyomov MN, Munk A, Gorvel L, Korenfeld
D, Cella M, Tung T and Klechevsky E: Modular expression analysis
reveals functional conservation between human Langerhans cells and
mouse cross-priming dendritic cells. J Exp Med. 212:743–757. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Barbosa CRR, Barton J, Shepherd AJ and
Mishto M: Mechanistic diversity in MHC class I antigen recognition.
Biochem J. 478:4187–4202. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Oh DS and Lee HK: Autophagy protein ATG5
regulates CD36 expression and anti-tumor MHC class II antigen
presentation in dendritic cells. Autophagy. 15:2091–2106. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Rühle PF, Fietkau R, Gaipl US and Frey B:
Development of a modular assay for detailed immunophenotyping of
peripheral human whole blood samples by multicolor flow cytometry.
Int J Mol Sci. 17:13162016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Mengos AE, Gastineau DA and Gustafson MP:
The CD14+HLA-DRlo/neg monocyte: An
immunosuppressive phenotype that restrains responses to cancer
immunotherapy. Front Immunol. 10:11472019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Trujillo-Ocampo A, Cho HW, Clowers M,
Pareek S, Ruiz-Vazquez W, Lee SE and Im JS: IL-7 during antigenic
stimulation using allogeneic dendritic cells promotes expansion of
CD45RA−CD62L+CD4+ invariant NKT
cells with Th-2 biased cytokine production profile. Front Immunol.
11:5674062020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mylonas KJ, Anderson J, Sheldrake TA,
Hesketh EE, Richards JA, Ferenbach DA, Kluth DC, Savill J and
Hughes J: Granulocyte macrophage-colony stimulating factor: A key
modulator of renal mononuclear phagocyte plasticity. Immunobiology.
224:60–74. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Shklovskaya E and Rizos H: MHC class I
deficiency in solid tumors and therapeutic strategies to overcome
it. Int J Mol Sci. 22:67412021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Pardi N, Hogan MJ, Porter FW and Weissman
D: mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov.
17:261–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Coughlan L, Kremer EJ and Shayakhmetov DM:
Adenovirus-based vaccines-a platform for pandemic preparedness
against emerging viral pathogens. Mol Ther. 30:1822–1849. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Guo J, De May H, Franco S, Noureddine A,
Tang L, Brinker CJ, Kusewitt DF, Adams SF and Serda RE: Cancer
vaccines from cryogenically silicified tumour cells functionalized
with pathogen-associated molecular patterns. Nat Biomed Eng.
6:19–31. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Subtil B, Cambi A, Tauriello DVF and de
Vries IJM: The therapeutic potential of tackling tumor-induced
dendritic cell dysfunction in colorectal cancer. Front Immunol.
12:7248832021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Guo L, Sang M, Liu Q, Fan X, Zhang X and
Shan B: The expression and clinical significance of
melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncol Lett.
6:55–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Gopanenko AV, Kosobokova EN and Kosorukov
VS: Main strategies for the identification of neoantigens. Cancers
(Basel). 12:28792020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Tomić S, Petrović A, Puač N, Škoro N,
Bekić M, Petrović ZL and Čolić M: Plasma-activated medium
potentiates the immunogenicity of tumor cell lysates for dendritic
cell-based cancer vaccines. Cancers (Basel). 13:16262021.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Polyzoidis S and Ashkan K:
DCVax®-L-developed by northwest biotherapeutics. Hum
Vaccin Immunother. 10:3139–3145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mott KR, Allen SJ, Zandian M, Akbari O,
Hamrah P, Maazi H, Wechsler SL, Sharpe AH, Freeman GJ and Ghiasi H:
Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on
DCs and allows productive infection and robust immune responses.
PLoS One. 9:e876172014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Stewart MP, Langer R and Jensen KF:
Intracellular delivery by membrane disruption: Mechanisms,
strategies, and concepts. Chem Rev. 118:7409–7531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Bello MB, Yusoff K, Ideris A, Hair-Bejo M,
Jibril AH, Peeters BPH and Omar AR: Exploring the prospects of
engineered Newcastle disease virus in modern vaccinology. Viruses.
12:4512020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Leroy H, Han M, Woottum M, Bracq L,
Bouchet J, Xie M and Benichou S: Virus-mediated cell-cell fusion.
Int J Mol Sci. 21:96442020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Russell CJ and Hurwitz JL: Sendai
virus-vectored vaccines that express envelope glycoproteins of
respiratory viruses. Viruses. 13:10232021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Huang TX, Tan XY, Huang HS, Li YT, Liu BL,
Liu KS, Chen X, Chen Z, Guan XY, Zou C and Fu L: Targeting
cancer-associated fibroblast-secreted WNT2 restores dendritic
cell-mediated antitumour immunity. Gut. 71:333–344. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cao L, Li W, Yang X, Zhang W, Li M, Zhang
H, Qin C, Chen X and Gao R: Inhibition of host Ogr1 enhances
effector CD8+ T-cell function by modulating acidic
microenvironment. Cancer Gene Ther. 28:1213–1224. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Aguilar-Cazares D, Chavez-Dominguez R,
Marroquin-Muciño M, Perez-Medina M, Benito-Lopez JJ, Camarena A,
Rumbo-Nava U and Lopez-Gonzalez JS: The systemic-level
repercussions of cancer-associated inflammation mediators produced
in the tumor microenvironment. Front Endocrinol (Lausanne).
13:9295722022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mizui M: Natural and modified IL-2 for the
treatment of cancer and autoimmune diseases. Clin Immunol.
206:63–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Glassman CR, Mathiharan YK, Jude KM, Su L,
Panova O, Lupardus PJ, Spangler JB, Ely LK, Thomas C, Skiniotis G
and Garcia KC: Structural basis for IL-12 and IL-23 receptor
sharing reveals a gateway for shaping actions on T versus NK cells.
Cell. 184:983–999.e24. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Takeda K, Nakayama M, Hayakawa Y, Kojima
Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM and Smyth MJ:
IFN-γ is required for cytotoxic T cell-dependent cancer genome
immunoediting. Nat Commun. 8:146072017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Duncan TJ, Rolland P, Deen S, Scott IV,
Liu DT, Spendlove I and Durrant LG: Loss of IFN gamma receptor is
an independent prognostic factor in ovarian cancer. Clin Cancer
Res. 13:4139–4145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ravaud A, Négrier S, Cany L, Merrouche Y,
Le Guillou M, Blay JY, Clavel M, Gaston R, Oskam R and Philip T:
Subcutaneous low-dose recombinant interleukin 2 and
alpha-interferon in patients with metastatic renal cell carcinoma.
Br J Cancer. 69:1111–1114. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Weinreich DM and Rosenberg SA: Response
rates of patients with metastatic melanoma to high-dose intravenous
interleukin-2 after prior exposure to alpha-interferon or low-dose
interleukin-2. J Immunother. 25:185–187. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wu YN, Zhang L, Chen T, Li X, He LH and
Liu GX: Granulocyte-macrophage colony-stimulating factor protects
mice against hepatocellular carcinoma by ameliorating intestinal
dysbiosis and attenuating inflammation. World J Gastroenterol.
26:5420–5436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Goyal G, Wong K, Nirschl CJ, Souders N,
Neuberg D, Anandasabapathy N and Dranoff G: PPARγ contributes to
immunity induced by cancer cell vaccines that secrete GM-CSF.
Cancer Immunol Res. 6:723–732. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhang SR, Nold MF, Tang SC, Bui CB, Nold
CA, Arumugam TV, Drummond GR, Sobey CG and Kim HA: IL-37 increases
in patients after ischemic stroke and protects from inflammatory
brain injury, motor impairment and lung infection in mice. Sci Rep.
9:69222019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jones DS II, Nardozzi JD, Sackton KL,
Ahmad G, Christensen E, Ringgaard L, Chang DK, Jaehger DE,
Konakondla JV, Wiinberg M, et al: Cell surface-tethered IL-12
repolarizes the tumor immune microenvironment to enhance the
efficacy of adoptive T cell therapy. Sci Adv. 8:eabi80752022.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Miyazaki T, Maiti M, Hennessy M, Chang T,
Kuo P, Addepalli M, Obalapur P, Sheibani S, Wilczek J, Pena R, et
al: NKTR-255, a novel polymer-conjugated rhIL-15 with potent
antitumor efficacy. J Immunother Cancer. 9:e0020242021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hamilton JA: GM-CSF in inflammation. J Exp
Med. 217:e201909452020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kumar V: Toll-like receptors in
sepsis-associated cytokine storm and their endogenous negative
regulators as future immunomodulatory targets. Int Immunopharmacol.
89:1070872020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Mercogliano MF, Bruni S, Mauro F, Elizalde
PV and Schillaci R: Harnessing Tumor necrosis factor alpha to
achieve effective cancer immunotherapy. Cancers (Basel).
13:5642021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang TT, Zhao YL, Peng LS, Chen N, Chen W,
Lv YP, Mao FY, Zhang JY, Cheng P, Teng YS, et al: Tumour-activated
neutrophils in gastric cancer foster immune suppression and disease
progression through GM-CSF-PD-L1 pathway. Gut. 66:1900–1911. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Bi E, Ma X, Lu Y, Yang M, Wang Q, Xue G,
Qian J, Wang S and Yi Q: Foxo1 and Foxp1 play opposing roles in
regulating the differentiation and antitumor activity of
TH9 cells programmed by IL-7. Sci Signal.
10:eaak97412017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Alizadeh D, Wong RA, Yang X, Wang D,
Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, et al: IL15
enhances CAR-T cell antitumor activity by reducing mTORC1 activity
and preserving their stem cell memory phenotype. Cancer Immunol
Res. 7:759–772. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hu HJ, Liang X, Li HL, Du CM, Hao JL, Wang
HY, Gu JF, Ni AM, Sun LY, Xiao J, et al: The armed oncolytic
adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor
cells from the self-state into the nonself-state besides direct
killing. Cell Death Dis. 11:10222020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Park A, Kim S, Jung IH and Byun JH: An
immune therapy model for effective treatment on inflammatory bowel
disease. PLoS One. 15:e02389182020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Berraondo P, Sanmamed MF, Ochoa MC,
Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME,
Ponz-Sarvise M, Castañón E and Melero I: Cytokines in clinical
cancer immunotherapy. Br J Cancer. 120:6–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Waldmann TA: Cytokines in cancer
immunotherapy. Cold Spring Harb Perspect Biol. 10:a0284722018.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Briukhovetska D, Dörr J, Endres S, Libby
P, Dinarello CA and Kobold S: Interleukins in cancer: From biology
to therapy. Nat Rev Cancer. 21:481–499. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Riley P, Glenny AM, Worthington HV,
Littlewood A, Fernandez Mauleffinch LM, Clarkson JE and McCabe MG:
Interventions for preventing oral mucositis in patients with cancer
receiving treatment: Cytokines and growth factors. Cochrane
Database Syst Rev. 11:CD0119902017.PubMed/NCBI
|
|
130
|
Esquivel-Velázquez M, Ostoa-Saloma P,
Palacios-Arreola MI, Nava-Castro KE, Castro JI and Morales-Montor
J: The role of cytokines in breast cancer development and
progression. J Interferon Cytokine Res. 35:1–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Hosokawa H and Rothenberg EV: Cytokines,
transcription factors, and the initiation of T-cell development.
Cold Spring Harb Perspect Biol. 10:a0286212018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Dayakar A, Chandrasekaran S, Kuchipudi SV
and Kalangi SK: Cytokines: Key determinants of resistance or
disease progression in visceral leishmaniasis: Opportunities for
novel diagnostics and immunotherapy. Front Immunol. 10:6702019.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wang X, Wong K, Ouyang W and Rutz S:
Targeting IL-10 family cytokines for the treatment of human
diseases. Cold Spring Harb Perspect Biol. 11:a0285482019.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ali MF, Driscoll CB, Walters PR, Limper AH
and Carmona EM: β-Glucan-activated human B lymphocytes participate
in innate immune responses by releasing proinflammatory cytokines
and stimulating neutrophil chemotaxis. J Immunol. 195:5318–5326.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Trottein F and Paget C: Natural killer T
cells and mucosal-associated invariant T cells in lung infections.
Front Immunol. 9:17502018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Isaeva OI, Sharonov GV, Serebrovskaya EO,
Turchaninova MA, Zaretsky AR, Shugay M and Chudakov DM:
Intratumoral immunoglobulin isotypes predict survival in lung
adenocarcinoma subtypes. J Immunother Cancer. 7:2792019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Fajgenbaum DC and June CH: Cytokine storm.
N Engl J Med. 383:2255–2273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Matthay MA, Zemans RL, Zimmerman GA, Arabi
YM, Beitler JR, Mercat A, Herridge M, Randolph AG and Calfee CS:
Acute respiratory distress syndrome. Nat Rev Dis Primers. 5:182019.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Eskilsson A, Shionoya K, Engblom D and
Blomqvist A: Fever during localized inflammation in mice is
elicited by a humoral pathway and depends on brain endothelial
interleukin-1 and interleukin-6 signaling and central EP3
receptors. J Neurosci. 41:5206–5218. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Kang S and Kishimoto T: Interplay between
interleukin-6 signaling and the vascular endothelium in cytokine
storms. Exp Mol Med. 53:1116–1123. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Tang XD, Ji TT, Dong JR, Feng H, Chen FQ,
Chen X, Zhao HY, Chen DK and Ma WT: Pathogenesis and treatment of
cytokine storm induced by infectious diseases. Int J Mol Sci.
22:130092021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Hemminki O, Dos Santos JM and Hemminki A:
Oncolytic viruses for cancer immunotherapy. J Hematol Oncol.
13:842020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Kaufman HL, Kohlhapp FJ and Zloza A:
Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug
Discov. 14:642–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Rahman MM and McFadden G: Oncolytic
viruses: Newest frontier for cancer immunotherapy. Cancers (Basel).
13:54522021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Innao V, Rizzo V, Allegra AG, Musolino C
and Allegra A: Oncolytic viruses and hematological malignancies: A
new class of immunotherapy drugs. Curr Oncol. 28:159–183. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Heidbuechel JPW and Engeland CE: Oncolytic
viruses encoding bispecific T cell engagers: A blueprint for
emerging immunovirotherapies. J Hematol Oncol. 14:632021.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Liu S, Liu F, Zhao M and Zhang J:
Antitumor efficacy of oncolytic herpes virus type 1 armed with
GM-CSF in murine uveal melanoma xenografts. Cancer Manag Res.
12:11803–11812. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Lühl NC, Zirngibl F, Dorneburg C, Wei J,
Dahlhaus M, Barth TF, Meyer LH, Queudeville M, Eckhoff S, Debatin
KM and Beltinger C: Attenuated measles virus controls pediatric
acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Haematologica. 99:1050–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Ammayappan A, Russell SJ and Federspiel
MJ: Recombinant mumps virus as a cancer therapeutic agent. Mol Ther
Oncolytics. 3:160192016. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Bommareddy PK, Patel A, Hossain S and
Kaufman HL: Talimogene laherparepvec (T-VEC) and other oncolytic
viruses for the treatment of melanoma. Am J Clin Dermatol. 18:1–15.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhang R, Cui Y, Guan X and Jiang X: A
recombinant human adenovirus type 5 (H101) combined with
chemotherapy for advanced gastric carcinoma: A retrospective cohort
study. Front Oncol. 11:7525042021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Omole RK, Oluwatola O, Akere MT, Eniafe J,
Agboluaje EO, Daramola OB, Ayantunji YJ, Omotade TI, Torimiro N,
Ayilara MS, et al: Comprehensive assessment on the applications of
oncolytic viruses for cancer immunotherapy. Front Pharmacol.
13:10827972022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Mardi A, Shirokova AV, Mohammed RN,
Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali
N, Zamani A and Akbari M: Biological causes of immunogenic cancer
cell death (ICD) and anti-tumor therapy; combination of oncolytic
virus-based immunotherapy and CAR T-cell therapy for ICD induction.
Cancer Cell Int. 22:1682022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ajina A and Maher J: Prospects for
combined use of oncolytic viruses and CAR T-cells. J Immunother
Cancer. 5:902017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Spiesschaert B, Angerer K, Park J and
Wollmann G: Combining oncolytic viruses and small molecule
therapeutics: Mutual benefits. Cancers (Basel). 13:33862021.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Schirrmacher V: Molecular mechanisms of
anti-neoplastic and immune stimulatory properties of oncolytic
Newcastle disease virus. Biomedicines. 10:5622022. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Globerson-Levin A, Waks T and Eshhar Z:
Elimination of progressive mammary cancer by repeated
administrations of chimeric antigen receptor-modified T cells. Mol
Ther. 22:1029–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Chang YH, Lau KS, Kuo RL and Horng JT:
dsRNA binding domain of PKR is proteolytically released by
enterovirus A71 to facilitate viral replication. Front Cell Infect
Microbiol. 7:2842017. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhang X, Wang S, Zhu Y, Zhang M, Zhao Y,
Yan Z, Wang Q and Li X: Double-edged effects of interferons on the
regulation of cancer-immunity cycle. Oncoimmunology.
10:19290052021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Ginting TE, Christian S, Larasati YO,
Suryatenggara J, Suriapranata IM and Mathew G: Antiviral
interferons induced by Newcastle disease virus (NDV) drive a
tumor-selective apoptosis. Sci Rep. 9:151602019. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Roulstone V, Mansfield D, Harris RJ,
Twigger K, White C, de Bono J, Spicer J, Karagiannis SN, Vile R,
Pandha H, et al: Antiviral antibody responses to systemic
administration of an oncolytic RNA virus: the impact of standard
concomitant anticancer chemotherapies. J Immunother Cancer.
9:e0026732021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Cheng JT, Wang YY, Zhu LZ, Zhang Y, Cai
WQ, Han ZW, Zhou Y, Wang XW, Peng XC, Xiang Y, et al: Novel
transcription regulatory sequences and factors of the immune
evasion protein ICP47 (US12) of herpes simplex viruses. Virol J.
17:1012020. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wang G, Kang X, Chen KS, Jehng T, Jones L,
Chen J, Huang XF and Chen SY: An engineered oncolytic virus
expressing PD-L1 inhibitors activates tumor neoantigen-specific T
cell responses. Nat Commun. 11:13952020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Arnone CM, Polito VA, Mastronuzzi A, Carai
A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F,
Salviato E, et al: Oncolytic adenovirus and gene therapy with
EphA2-BiTE for the treatment of pediatric high-grade gliomas. J
Immunother Cancer. 9:e0019302021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Shi T, Song X, Wang Y, Liu F and Wei J:
Combining oncolytic viruses with cancer immunotherapy: Establishing
a new generation of cancer treatment. Front Immunol. 11:6832020.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Guedan S and Alemany R: CAR-T cells and
oncolytic viruses: Joining forces to overcome the solid tumor
challenge. Front Immunol. 9:24602018. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Chianese A, Santella B, Ambrosino A,
Stelitano D, Rinaldi L, Galdiero M, Zannella C and Franci G:
Oncolytic viruses in combination therapeutic approaches with
epigenetic modulators: Past, present, and future perspectives.
Cancers (Basel). 13:27612021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Luo Q, Pan M, Feng H and Wang L: ABO blood
group antigen therapy: A potential new strategy against solid
tumors. Sci Rep. 11:162412021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
O'Brien RM, Cannon A, Reynolds JV, Lysaght
J and Lynam-Lennon N: Complement in tumourigenesis and the response
to cancer therapy. Cancers (Basel). 13:12092021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Khalili H, Wolpin BM, Huang ES,
Giovannucci EL, Kraft P, Fuchs CS and Chan AT: ABO blood group and
risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev.
20:1017–1020. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Akin S and Altundag K: Clinical
associations with ABO blood group and rhesus blood group status in
patients with breast cancer: A nationwide retrospective study of
3,944 breast cancer patients in Turkey. Med Sci Monit.
24:4698–4703. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Elkoshi Z: Cancer and autoimmune diseases:
A tale of two immunological opposites? Front Immunol.
13:8215982022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Kolev M and Markiewski MM: Targeting
complement-mediated immunoregulation for cancer immunotherapy.
Semin Immunol. 37:85–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Makunts T, Saunders IM, Cohen IV, Li M,
Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP and Abagyan R:
Myocarditis occurrence with cancer immunotherapy across indications
in clinical trial and post-marketing data. Sci Rep. 11:173242021.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Ermer T, Canavan ME, Maduka RC, Li AX,
Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H and
Boffa DJ: Association between food and drug administration approval
and disparities in immunotherapy use among patients with cancer in
the US. JAMA Netw Open. 5:e22195352022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Noman MZ, Hasmim M, Lequeux A, Xiao M,
Duhem C, Chouaib S, Berchem G and Janji B: Improving cancer
immunotherapy by targeting the hypoxic tumor microenvironment: New
opportunities and challenges. Cells. 8:10832019. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Kawashima S, Inozume T, Kawazu M, Ueno T,
Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, et
al: TIGIT/CD155 axis mediates resistance to immunotherapy in
patients with melanoma with the inflamed tumor microenvironment. J
Immunother Cancer. 9:e0031342021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R,
Shen K, Pan J, Wang Q and Xue W: Docetaxel remodels prostate cancer
immune microenvironment and enhances checkpoint inhibitor-based
immunotherapy. Theranostics. 12:4965–4979. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Lee HT, Lee SH and Heo YS: Molecular
interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in
immuno-oncology. Molecules. 24:11902019. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Capuano C, Pighi C, Battella S, De
Federicis D, Galandrini R and Palmieri G: Harnessing CD16-mediated
NK cell functions to enhance therapeutic efficacy of
tumor-targeting mAbs. Cancers (Basel). 13:25002021. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Li Q, Oduro PK, Guo R, Li R, Leng L, Kong
X, Wang Q and Yang L: Oncolytic viruses: Immunotherapy drugs for
gastrointestinal malignant tumors. Front Cell Infect Microbiol.
12:9215342022. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Burn OK, Prasit KK and Hermans IF:
Modulating the tumour microenvironment by intratumoural injection
of pattern recognition receptor agonists. Cancers (Basel).
12:38242020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Liu K, Cui JJ, Zhan Y, Ouyang QY, Lu QS,
Yang DH, Li XP and Yin JY: Reprogramming the tumor microenvironment
by genome editing for precision cancer therapy. Mol Cancer.
21:982022. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Sharma VP, Tang B, Wang Y, Duran CL,
Karagiannis GS, Xue EA, Entenberg D, Borriello L, Coste A, Eddy RJ,
et al: Live tumor imaging shows macrophage induction and
TMEM-mediated enrichment of cancer stem cells during metastatic
dissemination. Nat Commun. 12:73002021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Virant-Klun I, Skerl P, Novakovic S,
Vrtacnik-Bokal E and Smrkolj S: Similar population of CD133+ and
DDX4+ VSEL-like stem cells sorted from human embryonic stem cell,
ovarian, and ovarian cancer ascites cell cultures: The real
embryonic stem cells? Cells. 8:7062019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Yan Y, Chen Y, Yang F, Chen IH, Xiong Z,
Wang J, Lachman LB, Wang H and Yang XF: HLA-A2.1-restricted T cells
react to SEREX-defined tumor antigen CML66L and are suppressed by
CD4+CD25+ regulatory T cells. Int J Immunopathol Pharmacol.
20:75–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Wargo JA, Robbins PF, Li Y, Zhao Y,
El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS,
et al: Recognition of NY-ESO-1+ tumor cells by engineered
lymphocytes is enhanced by improved vector design and epigenetic
modulation of tumor antigen expression. Cancer Immunol Immunother.
58:383–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Yang L, Gu X, Yu J, Ge S and Fan X:
Oncolytic virotherapy: From bench to bedside. Front Cell Dev Biol.
9:7901502021. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Han W, Li W, Zhang X, Du Z, Liu X, Zhao X,
Wen X, Wang G, Hu JF and Cui J: Targeted breast cancer therapy by
harnessing the inherent blood group antigen immune system.
Oncotarget. 8:15034–15046. 2017. View Article : Google Scholar : PubMed/NCBI
|
